Active Pharmaceutical Ingredients (APIs) – Page 4

API nitrosamine risk exceedance during tech transfer to a new site: control strategy updates for CPPs/CMAs and continued process verification

Identifying the initial symptoms or signals of potential nitrosamine risk exceedance is critical for initiating an effective deviation investigation. Symptoms can manifest at various points in the production and testing…

API residual palladium OOS during process validation campaign: how to write a defensible deviation narrative for inspections

Recognizing the early symptoms or signals of an OOS result related to residual palladium is crucial. Common indicators include:Click to read the full article.

API hygroscopicity-driven degradation after re-crystallization parameter adjustment: risk-based approach to prevent repeat OOS across future API batches

Symptoms of API hygroscopicity-driven degradation may manifest during various stages of the production process or in finished product testing. Common indicators include:Click to read the full article.

API color / appearance change during stability pull at 6/12 months: supplier qualification gaps and incoming testing upgrades to close the loop

The onset of color or appearance changes in APIs can manifest in various ways. Symptoms observed may include:Click to read the full article.

API particle size distribution failure during FDA inspection readiness: risk-based approach to prevent repeat OOS across future API batches

Identifying symptoms or signals that an API's particle size distribution may not meet specifications is the first step in investigating a PSD failure. Symptoms may arise during various stages of…

API bulk density variability during EU GMP inspection preparation: root cause analysis (process vs lab) with CAPA effectiveness checks

Identifying symptoms early is vital in managing bulk density variability effectively. Symptoms may present in various forms, influencing batch quality and regulatory compliance. Below are some signals indicating potential issues…

API particle size distribution failure after cleaning validation requalification: control strategy updates for CPPs/CMAs and continued process verification

Identifying the initial symptoms of an API particle size distribution failure is crucial for timely investigation and resolution. Common signals may include:Click to read the full article.

API residual palladium OOS during routine release testing: supplier qualification gaps and incoming testing upgrades to close the loop

Identifying symptoms of OOS results is critical in the early stages of investigation. Some immediate flags that may indicate a residual palladium OOS situation include:Click to read the full article.

API endotoxin risk in sterile API after drying cycle optimization: how to justify reprocessing vs rejection to FDA/EMA inspectors

The first indication that there may be an endotoxin risk is often an Out of Specification (OOS) test result during routine monitoring of end-product samples. Beyond OOS results, symptoms may…

API stability failure at accelerated conditions during FDA inspection readiness: supplier qualification gaps and incoming testing upgrades to close the loop

Identifying the symptoms of API stability failure is the first step in a successful investigation. Symptoms may manifest as:Click to read the full article.

API starting material traceability gap after milling / micronization change: data integrity and chromatographic audit trail review steps

Recognizing the early signals of traceability gaps is vital for prompt investigation. Symptoms may include:Click to read the full article.

API residual solvent OOS after re-crystallization parameter adjustment: how to justify reprocessing vs rejection to FDA/EMA inspectors

The first step in addressing an OOS result is identifying the symptoms or signals that triggered the investigation. Typical signals to monitor may include:Click to read the full article.